See more : Ahluwalia Contracts (India) Limited (AHLUCONT.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Absci Corporation (ABSI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Absci Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Fortistar Sustainable Solutions Corp. (FSSI) Income Statement Analysis – Financial Results
- Tokyo Individualized Educational Institute, Inc. (4745.T) Income Statement Analysis – Financial Results
- Ping An Healthcare and Technology Company Limited (PANHF) Income Statement Analysis – Financial Results
- Associated British Foods plc (ASBFY) Income Statement Analysis – Financial Results
- Sundaram Finance Limited (SUNDARMFIN.BO) Income Statement Analysis – Financial Results
Absci Corporation (ABSI)
About Absci Corporation
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 5.72M | 5.75M | 4.78M | 4.78M | 2.06M |
| Cost of Revenue | 47.57M | 13.04M | 6.65M | 11.45M | 4.31M |
| Gross Profit | -41.85M | -7.29M | -1.87M | -6.67M | -2.25M |
| Gross Profit Ratio | -731.88% | -126.85% | -39.15% | -139.50% | -109.27% |
| Research & Development | 48.07M | 58.91M | 44.59M | 11.45M | 4.31M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 37.83M | 40.55M | 28.78M | 5.50M | 3.52M |
| Other Expenses | 35.33M | 13.04M | 6.65M | 1.13M | 491.00K |
| Operating Expenses | 121.23M | 112.50M | 80.02M | 18.08M | 8.33M |
| Cost & Expenses | 121.23M | 112.50M | 80.02M | 18.08M | 8.33M |
| Interest Income | 0.00 | 972.00K | 3.43M | 634.00K | 268.00K |
| Interest Expense | 1.01M | 972.00K | 3.43M | 634.00K | 268.00K |
| Depreciation & Amortization | 14.00M | 13.04M | 6.65M | 1.13M | 491.00K |
| EBITDA | -95.46M | -91.36M | -99.77M | -12.59M | -5.83M |
| EBITDA Ratio | -1,669.41% | -1,589.63% | -2,086.43% | -263.35% | -282.77% |
| Operating Income | -115.52M | -106.75M | -75.24M | -13.30M | -6.27M |
| Operating Income Ratio | -2,020.20% | -1,857.49% | -1,573.36% | -278.26% | -304.13% |
| Total Other Income/Expenses | 5.05M | 1.39M | -34.62M | -1.05M | -319.00K |
| Income Before Tax | -110.47M | -105.37M | -109.86M | -14.35M | -6.58M |
| Income Before Tax Ratio | -1,931.90% | -1,833.39% | -2,297.34% | -300.27% | -319.61% |
| Income Tax Expense | 100.00K | -461.00K | -8.90M | 216.00K | 217.00K |
| Net Income | -110.57M | -104.90M | -100.96M | -14.57M | -6.80M |
| Net Income Ratio | -1,933.65% | -1,825.37% | -2,111.25% | -304.79% | -330.15% |
| EPS | -1.20 | -1.15 | -1.09 | -0.16 | -0.07 |
| EPS Diluted | -1.20 | -1.15 | -1.09 | -0.16 | -0.07 |
| Weighted Avg Shares Out | 92.03M | 90.85M | 92.65M | 92.25M | 92.25M |
| Weighted Avg Shares Out (Dil) | 92.03M | 90.85M | 92.65M | 92.25M | 92.25M |
Absci Corporation (ABSI) Moves 16.8% Higher: Will This Strength Last?
Absci Corporation (ABSI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results
Initiated IND-enabling studies for ABS-101, a potential best-in-class anti-TL1A antibody Entered into collaboration with AstraZeneca for up to $247M in deal value, plus royalties Strengthened balance sheet raising approximately $86M in gross proceeds through underwritten common stock offering VANCOUVER, Wash....
Absci Announces Closing of Public Offering of Common Stock Including Full Exercise of the Underwriters' Option to Purchase Additional Shares
VANCOUVER, Wash., March 01, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company, today announced the closing of its underwritten public offering of 19,205,000 shares of its common stock at a public offering...
Absci Corporation (ABSI) Surges 10.0%: Is This an Indication of Further Gains?
Absci Corporation (ABSI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Absci Announces Pricing of Public Offering of Common Stock
VANCOUVER, Wash., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company, today announced the pricing of an underwritten public offering of 16,700,000 shares of its common stock at a public offering...
Absci Announces Proposed Public Offering of Common Stock
VANCOUVER, Wash., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company, announced today that it has commenced an underwritten public offering of $75.0 million of shares of its common stock. Absci...
Absci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and Optimized Using Generative AI
IND submission expected in Q1 2025; Phase 1 trials anticipated to initiate shortly after IND submission expected in Q1 2025; Phase 1 trials anticipated to initiate shortly after
Is Absci Corporation (ABSI) Outperforming Other Medical Stocks This Year?
Here is how Absci Corporation (ABSI) and Novo Nordisk (NVO) have performed compared to their sector so far this year.
Absci Appoints Professor Sir Mene Pangalos to its Board of Directors
VANCOUVER, Wash., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a generative AI drug creation company, today announced the appointment of seasoned R&D executive Professor Sir Menelas “Mene” Pangalos to its Board of Directors and as co-chair of Absci's...
Absci to Participate in the 26th Annual Needham Growth Conference
VANCOUVER, Wash. and NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating virtually in the upcoming 26th Annual Needham Growth Conference.
Source: https://incomestatements.info
Category: Stock Reports